This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Furiex Reports Fourth Quarter And Full Year 2012 Financial Results

Furiex will conduct a live conference call and webcast Thursday, March 7, 2013, at 9:00 a.m. ET to discuss its fourth quarter and full year 2012 results and financial outlook for 2013 as well as provide an overview of its business and pipeline. A Q&A session will follow. All interested parties can access the webcast through the Presentations & Events link in the Investors section of the Furiex website at The webcast will be archived shortly after the call for on-demand replay. The conference call will be broadcast live over the Internet and will also be available using the following direct dial numbers:

Participant dial-in:     +1.877.677.9122 (U.S./Canada)
+1.708.290.1401 (International)
Conference ID: 94872897

About Furiex

Furiex Pharmaceuticals is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of drug development programs by advancing them through the drug discovery and development process in a cost-efficient manner. Our drug development programs are designed and driven by a core team with extensive drug development experience. The company collaborates with pharmaceutical and biotechnology companies and has a diversified product portfolio and pipeline with multiple therapeutic candidates, including one Phase III-ready asset, two compounds in Phase III development, one of which is with a partner, three products on the market and a fourth approved in the United States but not yet launched. The company's mission is to develop innovative medicines faster and at a lower cost, thereby improving profitability and accelerating time to market while providing life-improving therapies for patients. For more information, visit

Except for historical information, all of the statements, expectations and assumptions contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although Furiex attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause actual results to differ materially include the following: the risks and expense of continuing the research and development activities of our existing candidates; inability of our existing collaborators to effectively market approved products for which we receive royalty and sales-based milestone payments; continuing losses and our potential need for additional financing; the risk of finding collaborators for our late-stage product candidates; progress of product candidates in clinical trials and regulatory approvals as it relates to receiving future milestone payments; changes in the safety and efficacy profile of our existing candidates as they progress through research and development; potential U.S. Food and Drug Administration changes to its regulatory guidance; new collaborative agreements that we might enter into in the future; the costs of defending or prosecuting any patent opposition or litigation necessary to protect our proprietary technologies; and the other risk factors set forth from time to time in the SEC filings for Furiex, copies of which can be found on our website.
(In thousands, except per share data)
Three Months Ended Twelve Months Ended
December 31, December 31,
2011 2012 2011 2012
Milestones $ $ $ $ 20,000
Royalties   1,985   9,211   4,490   20,508
Total revenue   1,985   9,211   4,490   40,508
Research and development expenses 6,079 14,586 44,202 69,505
Selling, general and administrative expenses 2,337 2,529 8,761 11,261
Depreciation and amortization   19   22   83   86
Total operating expenses   8,435   17,137   53,046   80,852
Operating loss (6,450) (7,926) (48,556) (40,344)
Interest expense 277 1,122 413 2,508
Other income, net   2   1   2   1
Loss before provision for income taxes (6,725) (9,047) (48,967) (42,851)
Provision for income taxes   (4)   5   14   14
Net loss $ (6,721) $ (9,052) $ (48,981) $ (42,865)
Net loss per basic and diluted share $ (0.68) $ (0.90) $ (4.96) $ (4.29)
Weighted-average shares used to compute net loss per basic and diluted share: 9,891 10,015 9,884 9,984
(In thousands, except share data)
December 31, December 31,
2011 2012
Current assets:
Cash and cash equivalents $ 33,628 $ 25,718
Short-term investments 10,000
Accounts receivable, net 1,985 11,745
Prepaid expenses   214   320
Total current assets 45,827 37,783
Property and equipment, net 181 118
Investments 7,500
Goodwill 49,116 49,116
Other assets     238
Total assets $ 95,124 $ 94,755
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable $ 147 $ 6,604
Accrued expenses 10,422 10,230
Current portion of long-term debt   1,351   5,405
Total current liabilities 11,920 22,239
Long-term debt, net 8,649 34,595
Other long-term liabilities   232   324
Total liabilities   20,801   57,158

Common stock, $0.001 par value, 40,000,000 shares authorized; 9,949,422 and 10,015,297

shares issued and outstanding
10 10

Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued or

Paid-in capital 158,438 164,577
Accumulated deficit   (84,125) (126,990)
Total shareholders’ equity   74,323   37,597
Total liabilities and shareholders’ equity $ 95,124 $ 94,755

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs